N
Nurix Therapeutics, Inc. (NRIX)
NGM – Real Time Price. Currency in USD
25.19
-0.32 (-1.23%)
Market open: Oct 23, 2026, 2:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
25.19
-0.32 (-1.23%)
Market open: Oct 23, 2026, 2:00 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $720.2M significantly exceed its total debt $65.3M, ensuring strong financial flexibility
Total current assets $1.1B exceed Total current liabilities $130.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.1), showcasing prudent financial management
The company has no interest-bearing debt, showcasing excellent financial strength
The company generates positive free cash flow $614.2M, supporting its financial health
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.44 | 4.66 | 10 | |
| Quick ratio | 8.44 | 4.27 | 10 | |
| Debt to Equity | 0.07 | 0.15 | 9.0 | |
| Debt to Assets | 0.05 | 0.11 | 9.0 | |
| Interest coverage | N/A | -3.18 | 10 | |
| Weighted average score | 9.6 | |||
| METRIC | 2022 (Nov 2022) | 2023 (Nov 2023) | 2024 (Nov 2024) | 2025 (Nov 2025) | TTM |
|---|---|---|---|---|---|
| Total Revenue | 39M | 77M | 55M | 84M | 702M |
| Gross Profit | 28M | 63M | 38M | 65M | 686M |
| Operating Income | -184M | -155M | -213M | -286M | 290M |
| Net Income | -180M | -144M | -194M | -264M | 295M |
| EBITDA | -173M | -141M | -197M | -267M | 306M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | 99.46 | 83.18 | 10 | |
| Operating margin % | 83.12 | -29.82 | 10 | |
| Net margin % | 81.69 | -41.34 | 10 | |
| EBITDA margin % | 83.66 | -26.03 | 10 | |
| Cash flow margin % | 91.47 | -43.91 | 10 | |
| Weighted average score | 10.0 | |||
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| ROA | -27.96 | -20.69 | 1.0 | |
| ROE | -36.83 | -17.54 | 1.0 | |
| ROIC | -33.64 | -18.98 | 1.0 | |
| ROCE | 43.10 | -25.49 | 10 | |
| Weighted average score | 3.3 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 179.55 | 49.46 | 10 |
| Next quarter | 141.26 | 30.92 | 10 |
| Current year | 711.86 | 177.12 | 10 |
| Next year | -85.39 | -190.38 | 1.0 |
| Weighted average score | 7.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 7342.93 | 714.07 | 683.95 | 723.54 | 10 |
| Y/Y | 8426.27 | 736.2 | 559.22 | 1122.1 | 10 |
| 3y average | 41.37 | -16.95 | 4.67 | -33.2 | 4.0 |
| 5y average | 44.18 | -55.15 | -4.15 | -406.76 | 3.3 |
| Weighted average score | 6.8 | ||||
| NAME | RATIO | INDUSTRY | 5Q TREND | SCORE |
|---|---|---|---|---|
| P/E | 11.03 | 20.20 | 8.4 | |
| PEG (5yr expected) | N/A | 1.20 | 1.0 | |
| P/S | 4.31 | 10.07 | 6.4 | |
| P/B | 2.93 | 4.38 | 6.2 | |
| Weighted average score | 5.5 | |||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | N/A | 1.20 | N/A |
| Payout ratio | N/A | 27.45 | N/A |
| 5-year dividend growth rate | N/A | 4.94 | N/A |
| Years of dividend increase | 0.00 | 0.00 | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | N/A | N/A |
| Intangible assets | N/A | N/A |
| Switching costs | N/A | N/A |
| Network effect | N/A | N/A |
| Economies of scale | N/A | N/A |
| Weighted average score | 1.0 | |